Anika Therapeutics Stock Analysis
ANIK Stock | USD 17.00 0.04 0.23% |
Anika Therapeutics is undervalued with Real Value of 19.83 and Target Price of 26.33. The main objective of Anika Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Anika Therapeutics is worth, separate from its market price. There are two main types of Anika Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Anika Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA.
Anika |
Anika Stock Analysis Notes
About 93.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.39. Some equities with similar Price to Book (P/B) outperform the market in the long run. Anika Therapeutics has Price/Earnings To Growth (PEG) ratio of 1.91. The entity recorded a loss per share of 6.64. The firm had not issued any dividends in recent years. Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts. Anika Therapeutics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 297 people. For more info on Anika Therapeutics please contact the company at 781 457 9000 or go to https://www.anika.com.Anika Therapeutics Quarterly Total Revenue |
|
Anika Therapeutics Investment Alerts
Anika Therapeutics generated a negative expected return over the last 90 days | |
Anika Therapeutics has high historical volatility and very poor performance | |
The company reported the previous year's revenue of 166.66 M. Net Loss for the year was (82.67 M) with profit before overhead, payroll, taxes, and interest of 96.78 M. | |
Anika Therapeutics currently holds about 87.78 M in cash with (1.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.01. | |
Over 93.0% of the company shares are held by institutions such as insurance companies | |
Latest headline from zacks.com: New Strong Sell Stocks for November 11th |
Anika Therapeutics Upcoming and Recent Events
4th of March 2024 Upcoming Quarterly Report | View | |
14th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
4th of March 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Anika Largest EPS Surprises
Earnings surprises can significantly impact Anika Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
1999-10-21 | 1999-09-30 | 0.01 | 4.0E-4 | -0.0096 | 96 | ||
2008-07-22 | 2008-06-30 | 0.06 | 0.07 | 0.01 | 16 | ||
2021-03-04 | 2020-12-31 | 0.14 | 0.12 | -0.02 | 14 |
Anika Therapeutics Environmental, Social, and Governance (ESG) Scores
Anika Therapeutics' ESG score is a quantitative measure that evaluates Anika Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Anika Therapeutics' operations that may have significant financial implications and affect Anika Therapeutics' stock price as well as guide investors towards more socially responsible investments.
Anika Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Capital Management Corp | 2024-09-30 | 290.4 K | Meros Investment Management, Lp | 2024-06-30 | 212.7 K | Stonepine Capital Management Llc | 2024-06-30 | 165.4 K | D. E. Shaw & Co Lp | 2024-06-30 | 152.9 K | Charles Schwab Investment Management Inc | 2024-06-30 | 150.1 K | Franklin Resources Inc | 2024-06-30 | 141.8 K | Northern Trust Corp | 2024-06-30 | 129.9 K | Arrowstreet Capital Limited Partnership | 2024-06-30 | 108.8 K | Aqr Capital Management Llc | 2024-06-30 | 107.4 K | Trigran Investments Inc | 2024-06-30 | 2.1 M | Blackrock Inc | 2024-06-30 | 1.6 M |
Anika Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 248.98 M.Anika Profitablity
The company has Profit Margin (PM) of (0.59) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.64) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.64.Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.32) | (0.30) | |
Return On Capital Employed | (0.37) | (0.35) | |
Return On Assets | (0.31) | (0.29) | |
Return On Equity | (0.39) | (0.37) |
Management Efficiency
Anika Therapeutics has return on total asset (ROA) of (0.0401) % which means that it has lost $0.0401 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4331) %, meaning that it created substantial loss on money invested by shareholders. Anika Therapeutics' management efficiency ratios could be used to measure how well Anika Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is expected to rise to -0.3 this year. Return On Capital Employed is expected to rise to -0.35 this year. At this time, Anika Therapeutics' Total Current Liabilities is quite stable compared to the past year. Change To Liabilities is expected to rise to about 3.6 M this year, although the value of Liabilities And Stockholders Equity will most likely fall to about 148 M.Last Reported | Projected for Next Year | ||
Book Value Per Share | 14.48 | 15.21 | |
Tangible Book Value Per Share | 13.65 | 14.33 | |
Enterprise Value Over EBITDA | (4.05) | (3.85) | |
Price Book Value Ratio | 1.56 | 1.73 | |
Enterprise Value Multiple | (4.05) | (3.85) | |
Price Fair Value | 1.56 | 1.73 | |
Enterprise Value | 511.9 M | 537.5 M |
The operational strategies employed by Anika Therapeutics management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Operating Margin (0.64) | Profit Margin (0.59) | Beta 0.857 | Return On Assets (0.04) | Return On Equity (0.43) |
Technical Drivers
As of the 15th of November 2024, Anika Therapeutics shows the Standard Deviation of 4.21, mean deviation of 1.85, and Risk Adjusted Performance of (0.08). Anika Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Anika Therapeutics Price Movement Analysis
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Anika Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Anika Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Anika Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Anika Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Anika Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Anika Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Anika Therapeutics Outstanding Bonds
Anika Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Anika Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Anika bonds can be classified according to their maturity, which is the date when Anika Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Boeing Co 2196 Corp BondUS097023DG73 | View | |
ANHEUSER BUSCH INBEV FIN Corp BondUS035242AN64 | View | |
ANHEUSER BUSCH INBEV FIN Corp BondUS035242AM81 | View | |
ANHEUSER BUSCH INBEV FIN Corp BondUS035242AB27 | View | |
US035229BP76 Corp BondUS035229BP76 | View | |
US035229BQ59 Corp BondUS035229BQ59 | View | |
ANHEUSER BUSCH PANIES LLC Corp BondUS03522AAJ97 | View | |
ANHEUSER BUSCH LLC ANHEUSER Corp BondUS03522AAG58 | View |
Anika Therapeutics Predictive Daily Indicators
Anika Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Anika Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Accumulation Distribution | 5835.54 | |||
Daily Balance Of Power | (0.06) | |||
Rate Of Daily Change | 1.0 | |||
Day Median Price | 16.85 | |||
Day Typical Price | 16.9 | |||
Price Action Indicator | 0.13 | |||
Period Momentum Indicator | (0.04) |
Anika Therapeutics Corporate Filings
13A | 8th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
10Q | 4th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 31st of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 23rd of October 2024 An amended filing to the original Schedule 13G | ViewVerify |
F4 | 4th of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 8th of August 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 11th of July 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
25th of June 2024 Other Reports | ViewVerify |
Anika Therapeutics Forecast Models
Anika Therapeutics' time-series forecasting models are one of many Anika Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Anika Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Anika Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Anika Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Anika shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Anika Therapeutics. By using and applying Anika Stock analysis, traders can create a robust methodology for identifying Anika entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (0.51) | (0.49) | |
Operating Profit Margin | (0.53) | (0.50) | |
Net Loss | (0.50) | (0.47) | |
Gross Profit Margin | 0.62 | 0.45 |
Current Anika Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Anika analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Anika analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
26.33 | Strong Buy | 2 | Odds |
Most Anika analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Anika stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Anika Therapeutics, talking to its executives and customers, or listening to Anika conference calls.
Anika Stock Analysis Indicators
Anika Therapeutics stock analysis indicators help investors evaluate how Anika Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Anika Therapeutics shares will generate the highest return on investment. By understating and applying Anika Therapeutics stock analysis, traders can identify Anika Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow | 86.3 M | |
Common Stock Shares Outstanding | 14.7 M | |
Total Stockholder Equity | 212.3 M | |
Tax Provision | -3.9 M | |
Quarterly Earnings Growth Y O Y | -0.505 | |
Property Plant And Equipment Net | 75 M | |
Cash And Short Term Investments | 72.9 M | |
Cash | 72.9 M | |
Accounts Payable | 9.9 M | |
Net Debt | -43.8 M | |
50 Day M A | 23.1036 | |
Total Current Liabilities | 31.1 M | |
Other Operating Expenses | 192.1 M | |
Non Current Assets Total | 107.3 M | |
Forward Price Earnings | 19.1205 | |
Non Currrent Assets Other | 14 M | |
Stock Based Compensation | 15.2 M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anika Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anika Therapeutics. If investors know Anika will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anika Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.51) | Earnings Share (6.64) | Revenue Per Share 11.139 | Quarterly Revenue Growth (0.07) | Return On Assets (0.04) |
The market value of Anika Therapeutics is measured differently than its book value, which is the value of Anika that is recorded on the company's balance sheet. Investors also form their own opinion of Anika Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Anika Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anika Therapeutics' market value can be influenced by many factors that don't directly affect Anika Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anika Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anika Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anika Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.